

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

U.S. Patent No.	:	7,527,969
Application No.	:	10/600,802
Applicant	:	Jennie P. Mather
Confirmation No.	:	9712
Filed	:	June 19, 2003
Issued	:	May 5, 2009
TC/A.U.	:	1642
Examiner	:	Davis, Minh Tam B
Customer No.	:	66522
Docket No.	:	1301.0045C
Title	:	Novel RAAG10 Cell Surface Target and a Family of Antibodies Recognizing That Target

**REVOCATION OF POWER OF ATTORNEY
AND NEW POWER OF ATTORNEY BY ASSIGNEE
AND STATEMENT UNDER 37 C.F.R. §3.73(b)**

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:

Transmitted herewith for filing in the subject application are a Revocation of Power of Attorney and New Power of Attorney by Assignee and Statement Under 37 CFR §3.73(b) (2 pages); and Exhibit A (5 pages).

The Commissioner is hereby authorized to charge payment of any additional fees required for the above-identified application or credit any overpayment to Deposit Account No. 05-0460.

Dated: December 11, 2009

Respectfully submitted by:

EDELL, SHAPIRO & FINNAN, LLC
CUSTOMER No. 66522
1901 Research Boulevard, Suite 400
Rockville, MD 20850
(301) 424-3640

/Jeffrey I. Auerbach/
Jeffrey I. Auerbach
Reg. No. 32680

In The United States Patent And Trademark Office

Revocation Of Power Of Attorney and New Power Of Attorney By Assignee and Statement of Assignee Under 37 C.F.R. §3.73(B)

Filed via EFS-Web
Mail Stop AF
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Raven Biotechnologies, Inc., the Assignee of the entire right, title, and interest:

- (I) Hereby revokes all previously granted powers of attorney given in the patents and applications identified in the attached **Exhibit A**; and
- (II) Hereby grants power to act, prosecute, and transact all business in the U.S. Patent and Trademark Office in connection with the applications, any applications claiming priority to these applications, and any patents issuing therefrom to the registered practitioners of **EDELL, SHAPIRO & FINNAN, LLC** associated with Customer Number **66522**.

Statement Under 37 C.F.R. §3.73(B)

The undersigned, having authority to act for Raven Biotechnologies, Inc. certifies that to the best of his knowledge and belief, Raven Biotechnologies, Inc. is the assignee of the entire right, title, and interest of the patents and applications identified in the attached **Exhibit A** as evidenced by Assignments of the Inventors previously recorded in the United States Patent & Trademark Office at the Reel and Frame numbers indicated below.

Please direct all correspondence concerning the applications to:

Jeffrey I. Auerbach, Reg. No. 32,680
EDELL, SHAPIRO & FINNAN, LLC
1901 Research Boulevard
Suite 400
Rockville, MD 20850
Tel: (301) 424-3640
Fax: (301) 762-4056
Email: epatent@usiplaw.com

CUSTOMER NUMBER: 66522

The undersigned (whose title is supplied below) are empowered to sign this statement on behalf of the Assignee.

Date: November 30, 2009

Signature: _____

Name: Timothy J. Mayer, Ph.D.

Title: Director of Intellectual Property

Company: Raven Biotechnologies, Inc. / MacroGenics, Inc.

Exhibit A

<u>Patent Application (Patent)</u>	<u>Filing Date (mm/dd/year)</u>	<u>Reel / Frame</u>	<u>New Atty Docket No.</u>	<u>Title of Invention</u>
10/902,588	07/28/2004	016018 / 0780 016025 / 0624 019470 / 0210	1301.0005C	Identification And Engineering Of Antibodies With Variant Fc Regions And Methods Of Using Same
12/018,126	01/22/2008	020499 / 0247	1301.0033C	Human Cancer Stem Cells
09/546,577 (US 6,436,704)	04/10/2000	010704 / 0921	1301.0035C	Human Pancreatic Epithelial Progenitor Cells And Methods Of Isolation And Use Thereof
10/119,601 (US 7,078,231)	04/09-2002	017302 / 0342	1301.0035CON	Human Pancreatic Epithelial Progenitor Cells And Methods Of Isolation And Use Thereof
09/466,011 (US 6,406,840)	12/17/1999	010468 / 0958 010702 / 0845 014852 / 0943	1301.0036C	Cell Arrays And The Uses Thereof
09/491,894 (US 6,541,225)	01/26/2000	010657 / 0769	1301.0037C	Methods And Compositions For Generating Human Monoclonal Antibodies

Exhibit A

<u>Patent Application (Patent)</u>	<u>Filing Date (mm/dd/year)</u>	<u>Reel / Frame</u>	<u>New Atty Docket No.</u>	<u>Title of Invention</u>
11/482,660	07/06/2006	018633 / 0648	1301.0037CON	Methods And Compositions For Generating Human Monoclonal Antibodies
09/545,659 (US 6,987,024)	04/10/2000	011037 / 0551	1301.0038C	Human Ovarian Mesothelial Cells And Methods Of Isolation And Uses Thereof
09/545,435 (US 6,416,999)	04/07/2000	010707 / 0277	1301.0039C	Human Mullerian Duct-Derived Epithelial Cells And Methods Of Isolation And Uses Thereof
10/117,895 (US 7,125,713)	04/05/2002	017299 / 0829	1301.0039DIV	Human Mullerian Duct-Derived Epithelial Cells And Methods Of Isolation And Uses Thereof
10/272,835 (US 7,148,038)	10/16/2002	013743 / 0032	1301.0040C	Antibodies That Bind To Cancer- Associated Antigen CD46 And Methods Of Use Thereof

Exhibit A

<u>Patent Application (Patent)</u>	<u>Filing Date (mm/dd/year)</u>	<u>Reel / Frame</u>	<u>New Atty Docket No.</u>	<u>Title of Invention</u>
11/524,344	09/19/2006	019455 / 0570	1301.0040CON	Antibodies That Bind To Cancer Associated Antigen CD46 And Methods Of Use Thereof
10/366,032	02/12/2003	014206 / 0707 014485 / 0769	1301.0041C	Human Fetal Bladder-Derived Epithelial Cells
10/944,083 (US 7,462,487)	09/17/2004	015576 / 0961	1301.0042C	Cell Culture Media
10/713,248 (US 7,405,061)	11/13/2003	014531 / 0360	1301.0043C	Antigen PIPA And Antibodies That Bind Thereto
10/448,766	05/30/2003	014611 / 0430	1301.0044C	Animal Model For Toxicology And Dose Prediction
10/600,802 (US 7,527,969)	06/19/2003	014633 / 0053	1301.0045C	Novel RAAG10 Cell Surface Target And A Family Of Antibodies Recognizing That Target
12/413,483	03/27/2009	022693 / 0482 022708 / 0807	1301.0045CON	Novel RAAG10 Cell Surface Target And A Family Of Antibodies Recognizing That Target

Exhibit A

<u>Patent Application (Patent)</u>	<u>Filing Date (mm/dd/year)</u>	<u>Reel / Frame</u>	<u>New Atty Docket No.</u>	<u>Title of Invention</u>
10/943,640	09/17/2004	015867 / 0060	1301.0046C	KID3 And KID3 Antibodies That Bind Thereto
11/349,327 (US 7,569,672)	02/06/2006	017410 / 0446	1301.0047C	Antibodies That Bind To EphA2and Methods Of Use Thereof
12/495,218	06/30/2009	017410 / 0446	1301.0047DIV	Antibodies That Bind To EphA2and Methods Of Use Thereof
11/147,942 (US 7,572,895)	06/07/2005	016972 / 0896	1301.0048C	Transferrin Receptor Antibodies
12/483,774	06/12/2009	016972 / 0896	1301.0048DIV	Transferrin Receptor Antibodies
11/344,814	01/31/2006	017419 / 0101	1301.0050C	LUCA2 And Antibodies That Bind Thereto
11/331,717	01/12/2006	017424 / 0266	1301.0049C	KID31 And Antibodies That Bind Thereto
11/346,779	02/02/2006	017489 / 0554	1301.0051C	Adam-9 Modulators
11/346,812 (US 7,572,896)	06/07/2005	017501 / 0910	1301.0052C	Transferrin Receptor Antibodies
12/497,439	07/02/2009	017501 / 0910	1301.0052CON	Antibodies To Oncostatin M Receptor

Exhibit A

<u>Patent Application (Patent)</u>	<u>Filing Date (mm/dd/year)</u>	<u>Reel / Frame</u>	<u>New Att'y Docket No.</u>	<u>Title of Invention</u>
11/937,470	11/08/2007	020536 / 0360	1301.0064C	TES7 And Antibodies That Bind Thereto